Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy.

ABSTRACT: Breast cancer is the most prevalent type of cancer among women. Several types of drugs, targeting the specific proteins expressed on the breast cancer cell surface (such as receptor tyrosine kinases and immune checkpoint regulators) and proteins involved in cell cycle and motility (including cyclin-dependent kinases, DNA stabilisers, and cytoskeleton modulators) are approved for different subtypes of breast cancer. However, breast cancer also has a poor response to conventional chemotherapy due to intrinsic and acquired resistance, and an Akt fingerprint is detectable in most drug-resistant cases. Overactivation of Akt and its upstream and downstream regulators in resistant breast cancer cells is considered a major potential target for novel anti-cancer therapies, suggesting that Akt signa

SUBMITTER: Kaboli PJ 

PROVIDER: S-EPMC8569340 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature